This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5 Stocks Set to Soar on Bullish Earnings

Hi-Tech Pharmacal

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

One potential earnings short-squeeze play in the biotechnology and drugs complex is Hi-Tech Pharmacal (HITK), which is set to release numbers on Wednesday before the market open. This company is a specialty manufacturer and marketer of prescription, over-the-counter and nutritional products. Wall Street analysts, on average, expect Hi-Tech Pharmacal to report revenue of $57.56 million on earnings of 68 cents per share.

The current short interest as a percentage of the float for Hi-Tech Pharmacal is sits at 4.9%. That means that out of the 10.58 million shares in the tradable float, 509,000 shares are sold short by the bears. This isn't a huge short interest, but it's more than enough to spark a decent short-covering rally post-earnings if the bulls get the news they're looking for.

From a technical perspective, HITK is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has been on a tear during the last two months, with shares soaring from a low of $27.35 to a recent high of $36.27 a share. During that sharp spike higher, shares of HITK have consistently made higher lows and higher highs, which is bullish technical price action. That move has now pushed HITK within range of triggering a near-term breakout trade post-earnings.

If you're bullish on HITK, then I would wait until after they report and look for long-biased trades if this stock can manage to take out some near-term overhead resistance levels at $36.27 to $36.49 a share with high volume. Look for volume on that move that registers near or above its three-month average action of 92,196 shares. If we get that move, then HITK will setup to re-test and possibly take out its next overhead resistance level at $38.16 a share. If $38.16 gets taken out with volume, then HITK could trend back towards $40 to $43 a share post-earnings.

I would avoid HITK or look for short-biased trades if after earnings it fails to trigger that breakout, and then drops below some near-term support at $34.53 a share with heavy volume. If we get that action, then HITK could easily take out its 50-day moving average of $33.21 a share, and then drop lower towards $30 to $29 a share post-earnings.

4 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs